# Mirabegron ER (Myrbetriq)

*Also known as: Mirabegron, Myrbetriq, Betmiga, Betanis*

Lifters discuss mirabegron for brown-fat activation and hoped-for fat loss, often comparing it with clenbuterol. The appeal is burning more calories with less nervous energy. Small human studies show metabolic changes, but have not established reliable fat loss.

Educational information only — not medical advice. Modelled values are not individual measurements or dosing recommendations.

## Dosage & duration

US Myrbetriq extended-release tablet label · adult overactive bladder

### Adult OAB starting treatment

**Product label**

- **Dose:** 25 mg per dose
- **How often:** Once daily by mouth
- **How long:** Ongoing treatment; reassess after 4–8 weeks

The label permits an increase to 50 mg daily when appropriate. Kidney/liver impairment and other medicines can limit the dose.

- [Astellas/DailyMed — Myrbetriq extended-release tablet label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d) — Astellas label available October 2026 (DailyMed update August 2024, prescribing information revised April 2021): adult overactive bladder 25 mg daily initially, possible 50 mg after 4–8 weeks; swallow whole; blood-pressure/retention precautions; CYP2D6 and digoxin interactions. Oral exposure is more than dose proportional; tablet and granule formulations are not mg-for-mg substitutes.

Swallow the ER tablet whole; do not split, chew or crush it. This is bladder-treatment context, not a brown-fat or fat-loss protocol.

Dose-context sources checked: 2026-10-09.

## At a glance

- **Why lifters look at it:** More calorie expenditure
  Sources or review notes: [3](https://pubmed.ncbi.nlm.nih.gov/25565203/).
- **Hoped-for advantage:** Less wired than clen
  Sources or review notes: [2](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d).
- **What is still missing:** Reliable fat-loss results
  Sources or review notes: [1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7190915/).

**Catalog evidence label (not clinical review):** Human RCT evidence

## Brown-fat activity versus fat loss



| Question | The hoped-for result | What the evidence shows |
| --- | --- | --- |
| Energy use | Burn more calories | Short-term metabolic changes |
| Body fat | Get leaner during a cut | No weight or fat loss in the small four-week study |
| Clen alternative | Less nervous energy | Feeling different does not prove lower heart or BP risk |

Blood pressure and heart rate can rise; experimental studies do not establish a bodybuilding course.

Visual sources checked: 2026-10-09.

- [Cypess et al. — activation of human brown adipose tissue](https://pubmed.ncbi.nlm.nih.gov/25565203/) — Original 2015 acute study: 12 men with detectable brown fat; 200 mg oral mirabegron versus placebo. Demonstrates research rationale, not a safe or effective long-term fat-loss regimen.
- [O’Mara et al. — mirabegron and human brown-fat activity](https://pmc.ncbi.nlm.nih.gov/articles/PMC7190915/) — Original 2020 open-label study in 14 healthy women: 100 mg/day extended-release tablets for 4 weeks (above approved adult OAB maximum). Brown-fat/metabolic measures changed, but body weight and fat mass did not; elevated heart rate/blood pressure and small uncontrolled design limit translation. Not a weight-loss dosing guide.
- [Astellas/DailyMed — Myrbetriq extended-release tablet label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d) — Astellas label available October 2026 (DailyMed update August 2024, prescribing information revised April 2021): adult overactive bladder 25 mg daily initially, possible 50 mg after 4–8 weeks; swallow whole; blood-pressure/retention precautions; CYP2D6 and digoxin interactions. Oral exposure is more than dose proportional; tablet and granule formulations are not mg-for-mg substitutes.

## Overview

## Why is mirabegron on a bodybuilding list?

The appeal is fat loss through a different pathway. Mirabegron stimulates receptors that can activate brown fat—a type of fat that burns energy to produce heat. The practical question is whether that can help a cut without the nervous energy associated with clenbuterol.

## Does the brown-fat idea translate into getting leaner?

An acute experiment found increased energy expenditure. A small four-week study also changed brown-fat and metabolic measures, but participants did not lose weight or fat mass. A short-term calorie measurement therefore should not be turned into a forecast of pounds lost.

## How do people compare it with clen?

Some people hope for a less stimulating option, but a person who tried it reported no clear fat-loss benefit. That account illustrates uncertainty, not an expected response. Feeling less wired is not a cardiovascular safety test: blood pressure and heart rate can rise with mirabegron.

## Why is the dose card about bladder treatment?

That is the established adult prescription context. The experimental metabolic studies do not supply a standard bodybuilding course. Kidney/liver function, interacting medicines and bladder-emptying problems can change suitability, and extended-release tablets should be swallowed whole.

## Relative timing model

Relative oral timing

**Output:** Mirabegron ER (Myrbetriq): relative timing (relative units).

Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.

Shows timing and dose scaling in relative units, not blood concentrations.

### Timing assumptions and scale

Iitsuka 2014 Table 2 Study 2: single fasting 50 mg OCAS tablet in 12 healthy Japanese men, mean terminal half-life 31.9 h and peak time 3.5 h. These source timings are used as a simplified scenario.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

- **Timing half-life used:** 31.9 hours
- **Absorption half-life assumed:** 0.5987955 hours
- **Reference amount for the relative scale:** 1 mg

- Absorption is inferred to reproduce the stated peak time with the stated terminal rate; this is not a fitted source absorption parameter.
- A single 1 mg input has a peak of 1 relative unit by definition. Repeated-dose addition and linear scaling are mathematical assumptions; the example dose does not calibrate the curve.
- The source curve has a faster distribution phase plus a slow terminal tail. A one-compartment curve cannot match its peak and overall exposure; no absolute amplitude is assigned.
- Actual oral exposure increases more than proportionally with dose. Linear relative scaling is only mathematical and must not be read as a blood-exposure ratio.
- The generic label terminal half-life is about 50 h in patients; that is a different source context and is not mixed into this study-specific timing.
- Food, sex, organ function and formulation affect exposure. This model does not represent immediate-release products or Myrbetriq granules.

### Model sources

- [Iitsuka et al. — mirabegron single- and multiple-dose pharmacokinetics](https://pmc.ncbi.nlm.nih.gov/articles/PMC3880470/) — Original 2014 study, Table 2 Study 2: single fasting 50 mg OCAS tablet in 12 healthy Japanese men, mean Cmax 30.1 ng/mL, Tmax 3.5 h, terminal half-life 31.9 h, AUC∞ 275 ng·h/mL. Dose nonlinearity and multiphasic elimination mean a peak/tail one-compartment fit is not an absolute model.
- [Astellas/DailyMed — Myrbetriq extended-release tablet label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d) — Astellas label available October 2026 (DailyMed update August 2024, prescribing information revised April 2021): adult overactive bladder 25 mg daily initially, possible 50 mg after 4–8 weeks; swallow whole; blood-pressure/retention precautions; CYP2D6 and digoxin interactions. Oral exposure is more than dose proportional; tablet and granule formulations are not mg-for-mg substitutes.

**Revision:** mirabegron-oral-relative-2026-10 · version 1

## Harm reduction

- **Interaction notes:** Monitor blood pressure and review urinary-retention risks. Some interacting medicines require monitoring or adjustment; severe uncontrolled hypertension is a label reason not to use it.

## Sources and review notes

Summary source check: 2026-10-09; see source notes 1, 2. This does not certify medical review of the whole page.

### Notes on the quick facts

- **Why lifters look at it:** Interest centers on brown-fat activation as another approach to cutting.
  Source check: 2026-10-09; not a medical review.
- **Hoped-for advantage:** This comparison reflects hoped-for and reported effects, not proof of lower cardiovascular risk.
  Source check: 2026-10-09; not a medical review.
- **What is still missing:** A small 4-week study increased metabolic activity without reducing weight or fat mass.
  Source check: 2026-10-09; not a medical review.

### References

1. [O’Mara et al. — mirabegron and human brown-fat activity](https://pmc.ncbi.nlm.nih.gov/articles/PMC7190915/) — Original 2020 open-label study in 14 healthy women: 100 mg/day extended-release tablets for 4 weeks (above approved adult OAB maximum). Brown-fat/metabolic measures changed, but body weight and fat mass did not; elevated heart rate/blood pressure and small uncontrolled design limit translation. Not a weight-loss dosing guide.
2. [Astellas/DailyMed — Myrbetriq extended-release tablet label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d) — Astellas label available October 2026 (DailyMed update August 2024, prescribing information revised April 2021): adult overactive bladder 25 mg daily initially, possible 50 mg after 4–8 weeks; swallow whole; blood-pressure/retention precautions; CYP2D6 and digoxin interactions. Oral exposure is more than dose proportional; tablet and granule formulations are not mg-for-mg substitutes.
3. [Cypess et al. — activation of human brown adipose tissue](https://pubmed.ncbi.nlm.nih.gov/25565203/) — Original 2015 acute study: 12 men with detectable brown fat; 200 mg oral mirabegron versus placebo. Demonstrates research rationale, not a safe or effective long-term fat-loss regimen.
4. [Iitsuka et al. — mirabegron single- and multiple-dose pharmacokinetics](https://pmc.ncbi.nlm.nih.gov/articles/PMC3880470/) — Original 2014 study, Table 2 Study 2: single fasting 50 mg OCAS tablet in 12 healthy Japanese men, mean Cmax 30.1 ng/mL, Tmax 3.5 h, terminal half-life 31.9 h, AUC∞ 275 ng·h/mL. Dose nonlinearity and multiphasic elimination mean a peak/tail one-compartment fit is not an absolute model.

---

**Canonical URL:** https://anabolicplotter.com/compounds/mirabegron/
**Methodology:** https://anabolicplotter.com/methodology/
**Plot:** https://anabolicplotter.com/plot?compound=mirabegron